TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00626808
Drug: No Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were no interventions. No subjects were enrolled in this retrospective database study.
Study: NCT01602393
Drug: CHF 5074 2x
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 2x, once a day in the morning for 48 weeks
Study: NCT00047112
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03213457
Drug: Estradiol/Norethindrone Acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT03892018
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
Study: NCT03105336
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT02229461
Drug: Naproxen Sodium (Aleve, BAY117031)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 220 mg qd or bid
Study: NCT02229461
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA 81 mg qd
Study: NCT05593094
Drug: ZN-A-1041 50mg BID
Normalized name: zinc acetate 50 MG
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 100mg BID
Normalized name: dimethicone 10 MG/ML / zinc oxide 100 MG/ML [A+D Diaper Rash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 200mg BID
Normalized name: zinc undecylenate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 400mg BID
Normalized name: zinc oxide 400 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 600mg BID
Normalized name: VITAMIN A/VITAMIN D/ZINC OXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 800mg BID
Normalized name: VITAMIN A/VITAMIN D/ZINC OXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 1000mg BID
Normalized name: zinc-DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day (BID) via oral administration
Study: NCT05593094
Drug: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-A-1041: twice a day (BID) via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Study: NCT05593094
Drug: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-A-1041: twice a day (BID) via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Study: NCT05593094
Drug: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-A-1041: twice a day (BID) via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
Study: NCT05593094
Drug: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-A-1041: twice a day (BID) via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Study: NCT05593094
Drug: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-A-1041: twice a day (BID) via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Study: NCT00676260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
Study: NCT02509169
Drug: TAE plus P53 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
Study: NCT00134901
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03685214
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
Study: NCT01108783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (encapsulated) Tablets QD/14 days
Study: NCT04476953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks exactly like the study drug, but it contains no active ingredient.
Study: NCT03333265
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
Study: NCT03953326
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
Study: NCT03953326
Drug: L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
Study: NCT02481869
Drug: Arthrocentesis/Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
Study: NCT03157635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per schedule described in Part 1 placebo arm.
Study: NCT01936350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
Study: NCT01830595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01111955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT02641652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
Study: NCT03774407
Drug: vaginal estriol
Normalized name: estriol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
Study: NCT00709956
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Study: NCT03493412
Drug: Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg/kg will be used as the dose of BH4
Study: NCT03493412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03617783
Drug: Prebiotin
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
Study: NCT03617783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-OEI
Study: NCT01815359
Drug: EPIC with FUDR and Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01105091
Drug: Flolan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per Prescribing Information
Study: NCT00391443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
Study: NCT02553460
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT02553460
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or NG.
Study: NCT02553460
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, IM or PO.
Study: NCT02553460
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin rescue PO or IV.
Study: NCT02570282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
Study: NCT01408602
Drug: MRC375
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
Study: NCT02570282
Drug: SST-6007
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
Study: NCT01408602
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
Study: NCT03372603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
Study: NCT01408602
Drug: MRC375 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
Study: NCT01028963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules once daily
Study: NCT01028963
Drug: CCX140-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX140-B capsules once daily (Group C)
Study: NCT01028963
Drug: CCX140-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX140-B capsules once daily (Group D)
Study: NCT01199055
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
Study: NCT03084718
Drug: Placebo pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control
Study: NCT01308424
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual dosing for 7 days
Study: NCT01601340
Drug: HQK-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 tablets, twice daily for 48 weeks
Study: NCT01696760
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325 mg twice a day
Study: NCT01267487
Drug: Heparin fixed doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
Study: NCT01267487
Drug: Heparin and protamine titration
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.
Study: NCT01332292
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
Study: NCT04542057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks
Study: NCT00352417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosing, 1 time daily for 12 weeks
Study: NCT00396565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
Study: NCT04607057
Drug: Parenteral Nutrition Solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN
Study: NCT00028977
Drug: herba scutellaria barbata
Normalized name: Scutellaria barbata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04201197
Drug: Inje cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug exposure
Study: NCT04201197
Drug: THC Cannabis extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug exposure
Study: NCT04201197
Drug: THC/CBD Cannabis Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug exposure
Study: NCT04511819
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered with food when possible.
Study: NCT00893269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo prior to sleep
Study: NCT01940510
Drug: RO5424802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose without (Day 1) and with (Day 17) co-administration of rifampin
Study: NCT00986310
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
Study: NCT00986310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
Study: NCT03247413
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, normal saline administered post-ablation at each lesion site
Study: NCT06742216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study: NCT03277755
Drug: SMV 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study: NCT01028482
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00619060
Drug: Topical Myristyl Nicotinate Cream
Normalized name: myristyl nicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
Study: NCT00619060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants apply topical placebo to one forearm once daily for 4 weeks.
Study: NCT05904002
Drug: pulmicort inhaler
Normalized name: Pulmicort Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
Study: NCT00745550
Drug: SB1518
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
Study: NCT01819870
Drug: Dilatrend SR capsule 32mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)
Study: NCT01819870
Drug: Dilatrend IR tablet 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)
Study: NCT00142025
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00247494
Drug: mycophenol mofetil (MMF, Cellcept®) 500 mg BID
Normalized name: mycophenolate mofetil 500 MG
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02299063
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06750445
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
Study: NCT00424294
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
Study: NCT00424294
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
Study: NCT00516425
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00516425
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00361127
Drug: isotonic saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02068131
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
Study: NCT03508635
Drug: Matching Placebo of CORT125134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02656069
Drug: G-Pen (glucagon injection)
Normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Study: NCT00578266
Drug: Cyclophosphamide,Campath IH and TBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)
Study: NCT00071422
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study: NCT00126789
Drug: Fentanyl Transdermal Matrix Patch ZR-02-01
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
Study: NCT02488525
Drug: Prophylactic treatment with Wilfactin
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
Study: NCT01707368
Drug: Daivobet® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Study: NCT01947959
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study: NCT04233424
Drug: D-PLEX
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
Study: NCT01721317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be available
Study: NCT01044108
Drug: '2-0453
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.